MedTrace Logo

Olmesartan Medoxomil in Atherosclerosis

NCT00185185 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2007-12-14

No results posted yet for this study

Summary

This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.

Conditions

Interventions

DRUG

Olmesartan medoxomil

DRUG

Atenolol

DRUG

Hydrochlorothiazide

tablets

DRUG

olmesartan medoxomil

tablets

DRUG

atenolol

tablets

Sponsors & Collaborators

  • Sankyo Pharma Gmbh

    lead INDUSTRY

Principal Investigators

  • Prof. Klaus O Stumpe, MD · Medizinische Poliklinik der Friedrich-Wilhelms-Universitat, Bonn, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Completion
2006-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185185 on ClinicalTrials.gov